$ICPT Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in INTERCEPT PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in INTERCEPT PHARMACEUTICALS, INC.. Get notifications about new insider transactions in INTERCEPT PHARMACEUTICALS, INC. for free.
Page: < prev 1 ... 5 6 7 8 9 10 11 12 13 ... 13 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 322.92 | 100 | 32,292 | 5,334 | 5.4 K to 5.3 K (-1.84 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 321.44 | 200 | 64,288 | 5,434 | 5.6 K to 5.4 K (-3.55 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 319.47 | 400 | 127,787 | 5,634 | 6 K to 5.6 K (-6.63 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 317.71 | 400 | 127,082 | 6,034 | 6.4 K to 6 K (-6.22 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 316.62 | 200 | 63,324 | 6,434 | 6.6 K to 6.4 K (-3.01 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 314.93 | 600 | 188,955 | 6,634 | 7.2 K to 6.6 K (-8.29 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 313.84 | 800 | 251,072 | 7,234 | 8 K to 7.2 K (-9.96 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 312.78 | 200 | 62,555 | 8,034 | 8.2 K to 8 K (-2.43 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 311.89 | 500 | 155,943 | 8,234 | 8.7 K to 8.2 K (-5.72 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 310.11 | 500 | 155,052 | 8,734 | 9.2 K to 8.7 K (-5.41 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 306.91 | 100 | 30,691 | 9,234 | 9.3 K to 9.2 K (-1.07 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 305.39 | 200 | 61,077 | 9,334 | 9.5 K to 9.3 K (-2.10 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Buy | M | 37.69 | 8,124 | 306,194 | 9,534 | 1.4 K to 9.5 K (+576.17 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Option Exercise | M | 21.50 | 316 | 6,794 | 11,882 | |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 345.62 | 316 | 109,216 | 2,166 | 2.5 K to 2.2 K (-12.73 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Buy | M | 21.50 | 316 | 6,794 | 2,482 | 2.2 K to 2.5 K (+14.59 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | M | 8.67 | 11,038 | 95,663 | 8,000 | |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 346.52 | 138 | 47,819 | 8,113 | 8.3 K to 8.1 K (-1.67 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 345.13 | 300 | 103,540 | 8,251 | 8.6 K to 8.3 K (-3.51 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 344.00 | 400 | 137,599 | 8,551 | 9 K to 8.6 K (-4.47 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 342.69 | 203 | 69,566 | 8,951 | 9.2 K to 9 K (-2.22 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 341.90 | 497 | 169,926 | 9,154 | 9.7 K to 9.2 K (-5.15 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 340.28 | 300 | 102,083 | 9,651 | 10 K to 9.7 K (-3.01 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 337.30 | 200 | 67,460 | 9,951 | 10.2 K to 10 K (-1.97 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 335.14 | 100 | 33,514 | 10,151 | 10.3 K to 10.2 K (-0.98 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 332.05 | 100 | 33,205 | 10,251 | 10.4 K to 10.3 K (-0.97 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 331.70 | 300 | 99,510 | 10,351 | 10.7 K to 10.4 K (-2.82 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 329.95 | 500 | 164,974 | 10,651 | 11.2 K to 10.7 K (-4.48 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 328.20 | 400 | 131,278 | 11,151 | 11.6 K to 11.2 K (-3.46 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 327.49 | 200 | 65,498 | 11,551 | 11.8 K to 11.6 K (-1.70 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 325.66 | 200 | 65,131 | 11,751 | 12 K to 11.8 K (-1.67 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 322.03 | 100 | 32,203 | 11,951 | 12.1 K to 12 K (-0.83 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 321.00 | 100 | 32,100 | 12,051 | 12.2 K to 12.1 K (-0.82 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 320.21 | 200 | 64,041 | 12,151 | 12.4 K to 12.2 K (-1.62 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 319.09 | 300 | 95,726 | 12,351 | 12.7 K to 12.4 K (-2.37 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 317.70 | 500 | 158,848 | 12,651 | 13.2 K to 12.7 K (-3.80 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 316.63 | 900 | 284,971 | 13,151 | 14.1 K to 13.2 K (-6.41 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 315.01 | 1,000 | 315,009 | 14,051 | 15.1 K to 14.1 K (-6.64 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 313.71 | 1,100 | 345,076 | 15,051 | 16.2 K to 15.1 K (-6.81 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 312.41 | 1,000 | 312,411 | 16,151 | 17.2 K to 16.2 K (-5.83 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 311.40 | 600 | 186,840 | 17,151 | 17.8 K to 17.2 K (-3.38 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 310.20 | 600 | 186,122 | 17,751 | 18.4 K to 17.8 K (-3.27 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 307.58 | 400 | 123,033 | 18,351 | 18.8 K to 18.4 K (-2.13 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 306.49 | 400 | 122,597 | 18,751 | 19.2 K to 18.8 K (-2.09 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Buy | M | 8.67 | 11,038 | 95,663 | 19,151 | 8.1 K to 19.2 K (+136.05 %) |
| Aug 12 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Option Exercise | M | 0.00 | 324 | 0 | 0 | |
| Aug 12 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Buy | M | 0.00 | 324 | 0 | 609 | 285 to 609 (+113.68 %) |
| Aug 12 2014 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Option Exercise | M | 0.00 | 324 | 0 | 0 | |
| Aug 12 2014 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Sell | S | 239.49 | 324 | 77,595 | 8,803 | 9.1 K to 8.8 K (-3.55 %) |
| Aug 12 2014 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Buy | M | 0.00 | 324 | 0 | 9,127 | 8.8 K to 9.1 K (+3.68 %) |
| Aug 12 2014 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Option Exercise | M | 0.00 | 368 | 0 | 0 | |
| Aug 12 2014 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Buy | M | 0.00 | 368 | 0 | 3,898 | 3.5 K to 3.9 K (+10.42 %) |
| Aug 12 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Option Exercise | M | 21.50 | 391 | 8,407 | 12,198 | |
| Aug 12 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Option Exercise | M | 0.00 | 324 | 0 | 0 | |
| Aug 12 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 239.49 | 391 | 93,641 | 2,166 | 2.6 K to 2.2 K (-15.29 %) |
| Aug 12 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Buy | M | 21.50 | 391 | 8,407 | 2,557 | 2.2 K to 2.6 K (+18.05 %) |
| Aug 12 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 238.28 | 1 | 238 | 2,166 | 2.2 K to 2.2 K (-0.05 %) |
| Aug 12 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 238.26 | 93 | 22,158 | 2,167 | 2.3 K to 2.2 K (-4.12 %) |
| Aug 12 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 238.25 | 6 | 1,430 | 2,260 | 2.3 K to 2.3 K (-0.26 %) |
| Aug 12 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 234.71 | 64 | 15,021 | 2,266 | 2.3 K to 2.3 K (-2.75 %) |
| Aug 12 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Buy | M | 0.00 | 324 | 0 | 2,330 | 2 K to 2.3 K (+16.15 %) |
| Aug 11 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Option Exercise | M | 0.00 | 324 | 0 | 0 | |
| Aug 11 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Buy | M | 0.00 | 324 | 0 | 1,656,582 | 1.7 M to 1.7 M (+0.02 %) |
| Aug 06 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 8.67 | 10,000 | 86,667 | 176,628 | |
| Aug 06 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 226.72 | 10,000 | 2,267,198 | 475,042 | 485 K to 475 K (-2.06 %) |
| Aug 06 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 8.67 | 10,000 | 86,667 | 485,042 | 475 K to 485 K (+2.11 %) |
| Jul 21 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Option Exercise | A | 210.36 | 348 | 73,205 | 348 | |
| Jul 21 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Grant | A | 0.00 | 285 | 0 | 285 | 0 to 285 |
| Jul 21 2014 | ICPT | INTERCEPT PHARMACE ... | Patel Sanj K | Director | Option Exercise | A | 210.36 | 551 | 115,908 | 551 | |
| Jul 21 2014 | ICPT | INTERCEPT PHARMACE ... | Patel Sanj K | Director | Grant | A | 0.00 | 452 | 0 | 452 | 0 to 452 |
| Jul 21 2014 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Option Exercise | A | 210.36 | 275 | 57,849 | 275 | |
| Jul 21 2014 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Grant | A | 0.00 | 226 | 0 | 8,803 | 8.6 K to 8.8 K (+2.63 %) |
| Jul 21 2014 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Option Exercise | A | 210.36 | 275 | 57,849 | 275 | |
| Jul 21 2014 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Grant | A | 0.00 | 226 | 0 | 3,530 | 3.3 K to 3.5 K (+6.84 %) |
| Jul 21 2014 | ICPT | INTERCEPT PHARMACE ... | Luca Benatti | Director | Option Exercise | A | 210.36 | 551 | 115,908 | 551 | |
| Jul 21 2014 | ICPT | INTERCEPT PHARMACE ... | Luca Benatti | Director | Grant | A | 0.00 | 452 | 0 | 492 | 40 to 492 (+1,130.00 %) |
| Jul 21 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Option Exercise | A | 210.36 | 275 | 57,849 | 275 | |
| Jul 21 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Grant | A | 0.00 | 226 | 0 | 2,006 | 1.8 K to 2 K (+12.70 %) |
| Jul 21 2014 | ICPT | INTERCEPT PHARMACE ... | SBLENDORIO GLENN | Director | Option Exercise | A | 210.36 | 551 | 115,908 | 551 | |
| Jul 21 2014 | ICPT | INTERCEPT PHARMACE ... | SBLENDORIO GLENN | Director | Grant | A | 0.00 | 452 | 0 | 452 | 0 to 452 |
| Jul 18 2014 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Option Exercise | A | 210.36 | 275 | 57,849 | 275 | |
| Jul 18 2014 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Option Exercise | M | 0.00 | 325 | 0 | 324 | |
| Jul 18 2014 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Grant | A | 0.00 | 226 | 0 | 2,818 | 2.6 K to 2.8 K (+8.72 %) |
| Jul 18 2014 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Buy | M | 0.00 | 325 | 0 | 2,592 | 2.3 K to 2.6 K (+14.34 %) |
| Jul 11 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Option Exercise | M | 21.50 | 391 | 8,407 | 12,589 | |
| Jul 11 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 222.50 | 158 | 35,155 | 1,780 | 1.9 K to 1.8 K (-8.15 %) |
| Jul 11 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 216.88 | 233 | 50,533 | 1,938 | 2.2 K to 1.9 K (-10.73 %) |
| Jul 11 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Buy | M | 21.50 | 391 | 8,407 | 2,171 | 1.8 K to 2.2 K (+21.97 %) |
| Jul 09 2014 | ICPT | INTERCEPT PHARMACE ... | TALLARIGO LORENZO | Director | Option Exercise | M | 9.82 | 2,000 | 19,645 | 4,923 | |
| Jul 09 2014 | ICPT | INTERCEPT PHARMACE ... | TALLARIGO LORENZO | Director | Sell | S | 244.00 | 1,000 | 244,000 | 0 | 1,000 to 0 (-100.00 %) |
| Jul 09 2014 | ICPT | INTERCEPT PHARMACE ... | TALLARIGO LORENZO | Director | Sell | S | 242.11 | 1,000 | 242,110 | 1,000 | 2 K to 1,000 (-50.00 %) |
| Jul 09 2014 | ICPT | INTERCEPT PHARMACE ... | TALLARIGO LORENZO | Director | Buy | M | 9.82 | 2,000 | 19,645 | 2,000 | 0 to 2 K |
| Jul 08 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Option Exercise | M | 37.69 | 1 | 38 | 109,999 | |
| Jul 08 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 250.00 | 1 | 250 | 1,410 | 1.4 K to 1.4 K (-0.07 %) |
| Jul 08 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Buy | M | 37.69 | 1 | 38 | 1,411 | 1.4 K to 1.4 K (+0.07 %) |
| Jul 03 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | M | 0.00 | 1,298 | 0 | 7,789 | |
| Jul 03 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Buy | M | 0.00 | 1,298 | 0 | 14,808 | 13.5 K to 14.8 K (+9.61 %) |
| Jul 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 10.40 | 4,000 | 41,600 | 26,703 | |
| Jul 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 0.00 | 1,623 | 0 | 9,735 | |
| Jul 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 247.65 | 849 | 210,257 | 15,027 | 15.9 K to 15 K (-5.35 %) |
| Jul 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 246.00 | 1,000 | 246,000 | 15,876 | 16.9 K to 15.9 K (-5.93 %) |
| Jul 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 244.75 | 2,000 | 489,499 | 16,876 | 18.9 K to 16.9 K (-10.60 %) |
| Jul 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 241.53 | 1,187 | 286,696 | 18,876 | 20.1 K to 18.9 K (-5.92 %) |
| Jul 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 10.40 | 4,000 | 41,600 | 20,063 | 16.1 K to 20.1 K (+24.90 %) |
| Jul 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 0.00 | 1,623 | 0 | 16,063 | 14.4 K to 16.1 K (+11.24 %) |
| Jul 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 8.67 | 10,000 | 86,667 | 186,628 | |
| Jul 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 0.00 | 4,868 | 0 | 29,206 | |
| Jul 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 250.61 | 10,000 | 2,506,121 | 475,042 | 485 K to 475 K (-2.06 %) |
| Jul 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 8.67 | 10,000 | 86,667 | 485,042 | 475 K to 485 K (+2.11 %) |
| Jul 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 0.00 | 4,868 | 0 | 475,042 | 470.2 K to 475 K (+1.04 %) |
| Jul 03 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | M | 0.00 | 649 | 0 | 3,894 | |
| Jul 03 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Buy | M | 0.00 | 649 | 0 | 8,113 | 7.5 K to 8.1 K (+8.70 %) |
| Jun 18 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 10.40 | 4,000 | 41,600 | 30,703 | |
| Jun 18 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 279.62 | 2,160 | 603,976 | 14,440 | 16.6 K to 14.4 K (-13.01 %) |
| Jun 18 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 278.55 | 840 | 233,982 | 16,600 | 17.4 K to 16.6 K (-4.82 %) |
| Jun 18 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 274.63 | 1,000 | 274,630 | 17,440 | 18.4 K to 17.4 K (-5.42 %) |
| Jun 18 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 10.40 | 4,000 | 41,600 | 18,440 | 14.4 K to 18.4 K (+27.70 %) |
| Jun 04 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 8.67 | 10,000 | 86,667 | 196,628 | |
| Jun 04 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 230.60 | 10,000 | 2,305,993 | 470,174 | 480.2 K to 470.2 K (-2.08 %) |
| Jun 04 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 8.67 | 10,000 | 86,667 | 480,174 | 470.2 K to 480.2 K (+2.13 %) |
| May 19 2014 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Option Exercise | M | 9.82 | 3,461 | 33,995 | 0 | |
| May 19 2014 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Option Exercise | M | 9.82 | 3,461 | 33,995 | 0 | |
| May 19 2014 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Buy | M | 9.82 | 3,461 | 33,995 | 8,577 | 5.1 K to 8.6 K (+67.65 %) |
| May 19 2014 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Buy | M | 9.82 | 3,461 | 33,995 | 5,116 | 1.7 K to 5.1 K (+209.12 %) |
| May 09 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Option Exercise | M | 0.00 | 325 | 0 | 324 | |
| May 09 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Buy | M | 0.00 | 325 | 0 | 2,629 | 2.3 K to 2.6 K (+14.11 %) |
| May 19 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 10.40 | 4,000 | 41,600 | 34,703 | |
| May 19 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 278.10 | 1,000 | 278,104 | 14,440 | 15.4 K to 14.4 K (-6.48 %) |
| May 19 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 277.00 | 2,000 | 554,000 | 15,440 | 17.4 K to 15.4 K (-11.47 %) |
| May 19 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 275.00 | 1,000 | 275,000 | 17,440 | 18.4 K to 17.4 K (-5.42 %) |
| May 19 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 272.00 | 743 | 202,096 | 18,440 | 19.2 K to 18.4 K (-3.87 %) |
| May 19 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 10.40 | 4,000 | 41,600 | 19,183 | 15.2 K to 19.2 K (+26.35 %) |
| May 09 2014 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Option Exercise | M | 0.00 | 325 | 0 | 324 | |
| May 09 2014 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Sell | S | 232.00 | 325 | 75,400 | 1,655 | 2 K to 1.7 K (-16.41 %) |
| May 09 2014 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Buy | M | 0.00 | 325 | 0 | 1,980 | 1.7 K to 2 K (+19.64 %) |
| May 09 2014 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Option Exercise | M | 0.00 | 367 | 0 | 368 | |
| May 09 2014 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Buy | M | 0.00 | 367 | 0 | 3,304 | 2.9 K to 3.3 K (+12.50 %) |
| May 09 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Option Exercise | M | 0.00 | 325 | 0 | 324 | |
| May 09 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 232.35 | 100 | 23,235 | 1,780 | 1.9 K to 1.8 K (-5.32 %) |
| May 09 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 228.69 | 62 | 14,179 | 1,880 | 1.9 K to 1.9 K (-3.19 %) |
| May 09 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Buy | M | 0.00 | 325 | 0 | 1,942 | 1.6 K to 1.9 K (+20.10 %) |
| May 09 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 251.25 | 65 | 16,331 | 1,617 | 1.7 K to 1.6 K (-3.86 %) |
| May 09 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 250.46 | 100 | 25,046 | 1,682 | 1.8 K to 1.7 K (-5.61 %) |
| May 09 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 252.31 | 100 | 25,231 | 1,782 | 1.9 K to 1.8 K (-5.31 %) |
| May 09 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 255.91 | 100 | 25,591 | 1,882 | 2 K to 1.9 K (-5.05 %) |
| May 09 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 254.00 | 100 | 25,400 | 1,982 | 2.1 K to 2 K (-4.80 %) |
| May 09 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 254.09 | 100 | 25,409 | 2,082 | 2.2 K to 2.1 K (-4.58 %) |
| May 09 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 261.42 | 100 | 26,142 | 2,182 | 2.3 K to 2.2 K (-4.38 %) |
| May 09 2014 | ICPT | INTERCEPT PHARMACE ... | TALLARIGO LORENZO | Director | Option Exercise | M | 0.00 | 367 | 0 | 368 | |
| May 09 2014 | ICPT | INTERCEPT PHARMACE ... | TALLARIGO LORENZO | Director | Sell | S | 232.00 | 367 | 85,144 | 0 | 367 to 0 (-100.00 %) |